An instinct about Atavistik? Roche signs $1.9B-plus deal

Privately held Atavistik Bio Inc. chalked a research collaboration with Roche AG to discover and develop small-molecule therapeutics against multiple targets for cardiovascular, renal and metabolic diseases.

Summary from BioWorld Articles.

Coverage 1 article · 1 outlet

1. BioWorld Articles 9h ago
   An instinct about Atavistik? Roche signs $1.9B-plus deal ↗